B. M. Nagalo

This study characterizes Morreton virus (MORV) as a safe and effective oncolytic virotherapy for liver cancers, showing tumor regression in animal models with lower doses than VSV.

This study develops a chimeric vesiculovirus (VMG) expressing MorV glycoprotein, showing anti-tumor effects in sarcoma models with in vitro efficacy and in vivo tumor reduction.

This study evaluates the in vivo safety and immunoactivity of Jurona virus in hepatocellular carcinoma using proteogenomic analysis, showing tumor regression and enhanced immune responses.

This study screens a small library of phenolic compounds in vitro and in silico to identify potential inhibitors of melanoma and non-melanoma skin cancer cells, finding several compounds with significant antitumor activity and selectivity.

This study shows that intratumoral MMR vaccine injections inhibit tumor growth and improve survival in mouse cancer models by enhancing cytotoxic T-cell responses.

This study identifies ethnicity-specific gene expression patterns in hepatocellular carcinoma and suggests ethnic differences in treatment efficacy.

This study shows that combining gemcitabine/cisplatin with CDK4/6 inhibitors improves efficacy and reduces toxicity in biliary tract cancers through mechanisms involving autophagy and RRM1 reduction.